GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals

GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals

Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link between KRas and GSK-3. To further elucidate the roles o...

Full description

Bibliographic Details
Main Authors: Stephen L. Abrams, Shaw M. Akula, Akshaya K. Meher, Linda S. Steelman, Agnieszka Gizak, Przemysław Duda, Dariusz Rakus, Alberto M. Martelli, Stefano Ratti, Lucio Cocco, Giuseppe Montalto, Melchiorre Cervello, Peter Ruvolo, Massimo Libra, Luca Falzone, Saverio Candido, James A. McCubrey
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cells
Subjects:
GSK-3β
targeted therapy
PDAC
breast cancer
KRas
β-catenin
Online Access:https://www.mdpi.com/2073-4409/10/4/816

Internet

https://www.mdpi.com/2073-4409/10/4/816

Similar Items